|
1
|
Podolec P and Matusik PT: New clinical
classification of rare cardiovascular diseases and disorders:
Relevance for cardiovascular research. Cardiovasc Res. 115:e77–e79.
2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kee PS, Chin PKL, Kennedy MA and Maggo
SDS: Pharmacogenetics of statin-induced myotoxicity. Front Genet.
11(575678)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Vinci P, Panizon E, Tosoni LM, Cerrato C,
Pellicori F, Mearelli F, Biasinutto C, Fiotti N, Di Girolamo FG and
Biolo G: Statin-associated myopathy: Emphasis on mechanisms and
targeted therapy. Int J Mol Sci. 22(11687)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wang J, Zou J, Shi Y, Zeng N, Guo D, Wang
H, Zhao C, Luan F, Zhang X and Sun J: Traditional Chinese medicine
and mitophagy: A novel approach for cardiovascular disease
management. Phytomedicine. 128(155472)2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chen C, Zhang QW, Ye Y and Lin LG:
Honokiol: A naturally occurring lignan with pleiotropic
bioactivities. Chin J Nat Med. 19:481–490. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rauf A, Olatunde A, Imran M, Alhumaydhi
FA, Aljohani ASM, Khan SA, Uddin MS, Mitra S, Emran TB, Khayrullin
M, et al: Honokiol: A review of its pharmacological potential and
therapeutic insights. Phytomedicine. 90(153647)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Prasher P, Fatima R, Sharma M, Tynybekov
B, Alshahrani AM, Ateşşahin DA, Sharifi-Rad J and Calina D:
Honokiol and its analogues as anticancer compounds: Current
mechanistic insights and structure-activity relationship. Chem Biol
Interact. 386(110747)2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dai SY, Qin WX, Yu S, Li C, Yang YH and
Pei YH: Honokiol and magnolol: A review of structure-activity
relationships of their derivatives. Phytochemistry.
223(114132)2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li X, Yuan Z, Wang Y, Wang W and Shi J:
Recent advances of honokiol: Pharmacological activities, manmade
derivatives and structure-activity relationship. Eur J Med Chem.
272(116471)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yang R, Cui L, Xu S, Zhong Y, Xu T, Liu J,
Lan Z, Qin S and Guo Y: Membrane-targeting amphiphilic honokiol
derivatives containing an oxazole moiety as potential
antibacterials against methicillin-resistant Staphylococcus aureus.
J Med Chem. 67:16858–16872. 2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liu A, Xun S, Zhou G, Zhang Y and Lin L:
Honokiol alleviates sepsis-associated cardiac dysfunction via
attenuating inflammation, apoptosis and oxidative stress. J Pharm
Pharmacol. 75:397–406. 2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang N, Kong R, Han W, Bao W, Shi Y, Ye L
and Lu J: Honokiol alleviates ulcerative colitis by targeting
PPAR-γ-TLR4-NF-κB signaling and suppressing gasdermin-D-mediated
pyroptosis in vivo and in vitro. Int Immunopharmacol.
111(109058)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhou Y, Tang J, Lan J, Zhang Y, Wang H,
Chen Q, Kang Y, Sun Y, Feng X, Wu L, et al: Honokiol alleviated
neurodegeneration by reducing oxidative stress and improving
mitochondrial function in mutant SOD1 cellular and mouse models of
amyotrophic lateral sclerosis. Acta Pharm Sin B. 13:577–597.
2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kim H, Lim CY and Chung MS: Magnolia
officinalis and its honokiol and magnolol constituents inhibit
human norovirus surrogates. Foodborne Pathog Dis. 18:24–30.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Qu WM, Yue XF, Sun Y, Fan K, Chen CR, Hou
YP, Urade Y and Huang ZL: Honokiol promotes non-rapid eye movement
sleep via the benzodiazepine site of the GABA(A) receptor in mice.
Br J Pharmacol. 167:587–598. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ferrucci L and Fabbri E: Inflammageing:
Chronic inflammation in ageing, cardiovascular disease, and
frailty. Nat Rev Cardiol. 15:505–522. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shaito A, Aramouni K, Assaf R, Parenti A,
Orekhov A, Yazbi AE, Pintus G and Eid AH: Oxidative stress-induced
endothelial dysfunction in cardiovascular diseases. Front Biosci
(Landmark Ed). 27(105)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Marchio P, Guerra-Ojeda S, Vila JM,
Aldasoro M, Victor VM and Mauricio MD: Targeting early
atherosclerosis: A focus on oxidative stress and inflammation. Oxid
Med Cell Longev. 2019(8563845)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Aktay I, Bitirim CV, Olgar Y, Durak A,
Tuncay E, Billur D, Akcali KC and Turan B: Cardioprotective role of
a magnolol and honokiol complex in the prevention of
doxorubicin-mediated cardiotoxicity in adult rats. Mol Cell
Biochem. 479:337–350. 2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fan S, Li X, Lin J, Chen S, Shan J and Qi
G: Honokiol inhibits tumor necrosis factor-alpha-stimulated rat
aortic smooth muscle cell proliferation via caspase- and
mitochondrial-dependent apoptosis. Inflammation. 37:17–26.
2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yuan Y, Zhou X, Wang Y, Wang Y, Teng X and
Wang S: Cardiovascular modulating effects of magnolol and honokiol,
two polyphenolic compounds from traditional Chinese
medicine-Magnolia officinalis. Curr Drug Target. 21:559–572.
2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liu Y, Cheng P and Wu AH: Honokiol
inhibits carotid artery atherosclerotic plaque formation by
suppressing inflammation and oxidative stress. Aging (Albany NY).
12:8016–8028. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Liou KT, Lin SM, Huang SS, Chih CL and
Tsai SK: Honokiol ameliorates cerebral infarction from
ischemia-reperfusion injury in rats. Planta Med. 69:130–134.
2003.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liu J, Tang M, Li T, Su Z, Zhu Z, Dou C,
Liu Y, Pei H, Yang J, Ye H and Chen L: Honokiol ameliorates
post-myocardial infarction heart failure through Ucp3-mediated
reactive oxygen species inhibition. Front Pharmacol.
13(811682)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhao C and Liu ZQ: Comparison of
antioxidant abilities of magnolol and honokiol to scavenge radicals
and to protect DNA. Biochimie. 93:1755–1760. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wang D, Cao L, Zhou X, Wang G, Ma Y, Hao X
and Fan H: Mitigation of honokiol on fluoride-induced mitochondrial
oxidative stress, mitochondrial dysfunction, and cognitive deficits
through activating AMPK/PGC-1α/Sirt3. J Hazard Mater.
437(129381)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Caballero EP, Mariz-Ponte N, Rigazio CS,
Santamaria MH and Corral RS: Honokiol attenuates oxidative
stress-dependent heart dysfunction in chronic Chagas disease by
targeting AMPK/NFE2L2/SIRT3 signaling pathway. Free Radical Biol
Med. 156:113–124. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lin A, Miano JM, Fisher EA and Misra A:
Chronic inflammation and vascular cell plasticity in
atherosclerosis. Nat Cardiovasc Res. 3:1408–1423. 2024.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Guzik TJ, Nosalski R, Maffia P and
Drummond GR: Immune and inflammatory mechanisms in hypertension.
Nat Rev Cardiol. 21:396–416. 2024.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Boulet J, Sridhar VS, Bouabdallaoui N,
Tardif JC and White M: Inflammation in heart failure:
Pathophysiology and therapeutic strategies. Inflamm Res.
73:709–723. 2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lee J, Jung E, Park J, Jung K, Lee S, Hong
S, Park J, Park E, Kim J, Park S and Park D: Anti-inflammatory
effects of magnolol and honokiol are mediated through inhibition of
the downstream pathway of MEKK-1 in NF-kappaB activation signaling.
Planta Med. 71:338–343. 2005.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tang X, Yao K, Zhang L, Yang Y and Yao H:
Honokiol inhibits H2O2-induced apoptosis in
human lens epithelial cells via inhibition of the mitogen-activated
protein kinase and Akt pathways. Eur J Pharmacol. 650:72–78.
2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ye JS, Chen L, Lu YY, Lei SQ, Peng M and
Xia ZY: SIRT3 activator honokiol ameliorates
surgery/anesthesia-induced cognitive decline in mice through
anti-oxidative stress and anti-inflammatory in hippocampus. CNS
Neurosci Ther. 25:355–366. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhu X, Wang Z, Hu C, Li Z and Hu J: .
Honokiol suppresses TNF-α-induced migration and matrix
metalloproteinase expression by blocking NF-κB activation via the
ERK signaling pathway in rat aortic smooth muscle cells. Acta
Histochem. 116:588–595. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Murakami Y, Kawata A, Seki Y, Koh T,
Yuhara K, Maruyama T, Machino M, Ito S, Kadoma Y and Fujisawa S:
Comparative inhibitory effects of magnolol, honokiol, eugenol and
bis-eugenol on cyclooxygenase-2 expression and nuclear factor-kappa
B activation in RAW264.7 macrophage-like cells stimulated with
fimbriae of Porphyromonas gingivalis. In Vivo. 26:941–950.
2012.PubMed/NCBI
|
|
36
|
Montecino-Garrido H, Méndez D,
Araya-Maturana R, Millas-Vargas JP, Wehinger S and Fuentes E: In
vitro effect of mitochondria-targeted triphenylphosphonium-based
compounds (Honokiol, Lonidamine, and Atovaquone) on the platelet
function and cytotoxic activity. Front Pharmacol.
13(893873)2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Seok YM, Cho HJ, Cha BY, Woo JT and Kim
IK: Honokiol attenuates vascular contraction through the inhibition
of the RhoA/Rho-kinase signalling pathway in rat aortic rings. J
Pharm Pharmacol. 63:1244–1251. 2011.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Onselaer MB, Nagy M, Pallini C, Pike JA,
Perrella G, Quintanilla LG, Eble JA, Poulter NS, Heemskerk JWM and
Watson SP: Comparison of the GPVI inhibitors losartan and honokiol.
Platelets. 31:187–197. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Elbarbry F and Moshirian N: The modulation
of arachidonic acid metabolism and blood pressure-lowering effect
of honokiol in spontaneously hypertensive rats. Molecules.
27(3396)2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Chi Z, Le TPH, Lee SK, Guo E, Kim D, Lee
S, Seo SY and Lee SY, Kim JH and Lee SY: Honokiol ameliorates
angiotensin II-induced hypertension and endothelial dysfunction by
inhibiting HDAC6-mediated cystathionine γ-lyase degradation. J Cell
Mol Med. 24:10663–10676. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lv D, Luo M, Yan J, Yang X and Luo S:
Protective effect of sirtuin 3 on CLP-induced endothelial
dysfunction of early sepsis by inhibiting NF-κB and NLRP3 signaling
pathways. Inflammation. 44:1782–1792. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
He A, Yu H, Hu Y, Chen H, Li X, Shen J,
Zhuang R, Chen Y, Sasmita BR, Luo M and Lv D: Honokiol improves
endothelial function in type 2 diabetic rats via alleviating
oxidative stress and insulin resistance. Biochem Biophys Res
Commun. 600:109–116. 2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tan Z, Liu H, Song X, Ling Y, He S, Yan Y,
Yan J, Wang S, Wang X and Chen A: Honokiol post-treatment
ameliorates myocardial ischemia/reperfusion injury by enhancing
autophagic flux and reducing intracellular ROS production. Chem
Biol Interact. 307:82–90. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lv L, Kong Q, Li Z and Zhang Y, Chen B, Lv
L and Zhang Y: Honokiol provides cardioprotection from myocardial
ischemia/reperfusion injury (MI/RI) by inhibiting mitochondrial
apoptosis via the PI3K/AKT signaling pathway. Cardiovasc Ther.
2022(1001692)2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wang Y, Zhang ZZ, Wu Y, Zhan J, He XH and
Wang YL: Honokiol protects rat hearts against myocardial ischemia
reperfusion injury by reducing oxidative stress and inflammation.
Exp Ther Med. 5:315–319. 2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Pillai VB, Samant S, Sundaresan NR,
Raghuraman H, Kim G, Bonner MY, Arbiser JL, Walker DI, Jones DP,
Gius D and Gupta MP: Honokiol blocks and reverses cardiac
hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun.
6(6656)2015.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhong C, Wang C, Li W, Li W, Chen X, Guo
J, Feng Y and Wu X: A derivative of honokiol HM568 has an
anti-neuroinflammatory effect in Parkinson's disease. Chem Biol
Interact. 403(111212)2024.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Qiu L, Xu R, Wang S, Li S, Sheng H, Wu J
and Qu Y: Honokiol ameliorates endothelial dysfunction through
suppression of PTX3 expression, a key mediator of
IKK/IkappaB/NF-ĸB, in atherosclerotic cell model. Exp Mol Med.
47(e171)2015.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Lin X, Zhang H, Chu Y, Zhang Y, Xu C, Xie
H, Ruan Q, Lin J, Huang CK and Chai D: Honokiol ameliorates
angiotensin II-induced cardiac hypertrophy by promoting
dissociation of the Nur77-LKB1 complex and activating the AMPK
pathway. J Cell Mol Med. 28(e18028)2024.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zhu J, Ning RB, Lin XY, Chai DJ, Xu CS,
Xie H, Zeng JZ and Lin JX: Retinoid X receptor agonists inhibit
hypertension-induced myocardial hypertrophy by modulating
LKB1/AMPK/p70S6K signaling pathway. Am J Hypertens. 27:1112–1124.
2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Cai X, Jiang X, Zhao M, Su K, Tang M, Hong
F, Ye N, Zhang R, Li N, Wang L, et al: Identification of the target
protein and molecular mechanism of honokiol in anti-inflammatory
action. Phytomedicine. 109(154617)2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Huang PP, Fu J, Liu LH, Wu KF, Liu HX, Qi
BM, Liu Y and Qi BL: Honokiol antagonizes doxorubicin-induced
cardiomyocyte senescence by inhibiting TXNIP-mediated NLRP3
inflammasome activation. Int J Mol Med. 45:186–194. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Guo Y, Liu N, Zhang J, Yang J, Kang W, Lu
T, Guo Y and Yao Y: Application of honokiol in preparation of
medicine for treating myocardial infarction. China Patent
CN114588136A. Filed April 7, 2022; issued June 7, 2022.
|
|
54
|
Miao GP, Han J, Zhang JF, Tong G and Wu Y:
A kind of active ingredient of Chinese herbs composition for
treating cardiovascular and cerebrovascular disease China Patent
CN109045045A. Filed August 14, 2018; issued December 21, 2018.
|
|
55
|
Li WM, Feng YF, Zhu HN, Yu R and Li Y: A
kind of compound and its preparation method and application. China
Patent CN108033927A. Filed October 27, 2017; issued May 15,
2018.
|
|
56
|
Guang B, Yang T, Dong RH, Peng X, Liu I,
Xie J, Qin L, Xu G and Liao X: The new application of honokiol
derivative. China Patent CN109771431A. Filed January 31, 2019;
issued May 21, 2019.
|
|
57
|
Zhang P, Liu Y, Zhang Y and Gu J:
Application of magnolol or aromatic ring amino substituted
derivative of honokiol in preparation of anti-myocardial ischemia
drugs and pharmaceutical composition. China Patent CN115581690A.
Filed July 5, 2021; issued January 10, 2023.
|
|
58
|
Xian X, Zhao X, Zhou X, Liu H, Li C, Wu X,
Chen Y, Ye K, Yang H, Li M, et al: Honokiol attenuates oxidative
stress and vascular calcification via the upregulation of heme
oxygenase-1 in chronic kidney disease. Toxicol Appl Pharmacol.
499(117318)2025.PubMed/NCBI View Article : Google Scholar
|
